Coronary sinus neuropeptide y levels and adverse outcomes in patients with stable chronic heart failure

Coronary sinus neuropeptide y levels and adverse outcomes in patients with stable chronic heart failure

<p><strong>Importance:</strong> Chronic heart failure (CHF) is associated with increased sympathetic drive and may increase expression of the cotransmitter neuropeptide Y (NPY) within sympathetic neurons.</p> <p><strong>Objective:</strong> To determine wheth...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Ajijola, O, Chatterjee, N, Gonzales, M, Gornbein, J, Liu, K, Li, D, Paterson, D, Shivkumar, K, Singh, J, Herring, N
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	American Medical Association 2019

Míreanna comhchosúla

Neuropeptide‐Y levels in ST‐segment–elevation myocardial infarction: relationship with coronary microvascular function, heart failure, and mortality
de réir: Gibbs, T, et al.
Foilsithe / Cruthaithe: (2022)

Neuropeptide‐Y Levels in ST‐Segment–Elevation Myocardial Infarction: Relationship With Coronary Microvascular Function, Heart Failure, and Mortality
de réir: Thomas Gibbs, et al.
Foilsithe / Cruthaithe: (2022-07-01)

The cardiac sympathetic co-transmitter neuropeptide Y is pro-arrhythmic following ST-elevation myocardial infarction despite beta-blockade
de réir: Kalla, M, et al.
Foilsithe / Cruthaithe: (2019)

Bayliss Starling Prize Lecture 2023: Neuropeptide‐Y being ‘unsympathetic’ to the broken hearted
de réir: Bussmann, B, et al.
Foilsithe / Cruthaithe: (2024)

Peripheral cardiac sympathetic hyperactivity in cardiovascular disease: role of neuropeptides
de réir: Shanks, J, et al.
Foilsithe / Cruthaithe: (2013)

Ventricular tachycardia in ischemic heart disease substrates
de réir: Olujimi A. Ajijola, et al.
Foilsithe / Cruthaithe: (2014-01-01)

Circulating neuropeptide Y dynamics and performance during exercise in heart failure patients with contemporary medical and device therapy
de réir: Thamali Ayagama, et al.
Foilsithe / Cruthaithe: (2025-03-01)

Neuropeptide Y reduces acetylcholine release and vagal bradycardia via a Y2 receptor-mediated, protein kinase C-dependent pathway.
de réir: Herring, N, et al.
Foilsithe / Cruthaithe: (2008)

Endothelial nitric oxide synthase and heart rate.
de réir: Herring, N, et al.
Foilsithe / Cruthaithe: (2002)

Atlas of electrophysiology in heart failure /
de réir: Shivkumar, Kalyanam
Foilsithe / Cruthaithe: (2005)

RNA sequencing reveals novel transcripts from sympathetic stellate ganglia during cardiac sympathetic hyperactivity
de réir: Bardsley, E, et al.
Foilsithe / Cruthaithe: (2018)

Relationship of plasma neuropeptide Y with angiographic, electrocardiographic and coronary physiology indices of reperfusion during ST elevation myocardial infarction
de réir: Cuculi, F, et al.
Foilsithe / Cruthaithe: (2013)

The role of neuropeptide Y in cardiovascular health and disease
de réir: Tan, C, et al.
Foilsithe / Cruthaithe: (2018)

Selective If-channel inhibitor ivabradine in the treatment of sinus tachycardia in coronary heart disease patients with acute heart failure and inferior myocardial infarction
de réir: S. A. Sayganov, et al.
Foilsithe / Cruthaithe: (2010-06-01)

Heart failure biomarkers in revascularized patients with stable coronary heart disease as clinical outcome predictors
de réir: Ivica Bošnjak, et al.
Foilsithe / Cruthaithe: (2024-09-01)

NO-cGMP dependent pathway and the modulation of vagal control of heart rate
de réir: Herring, N, et al.
Foilsithe / Cruthaithe: (2000)

Coronary sinus ostium in the lateral right atrium: Implications for the electrophysiologist
de réir: Nilesh Mathuria, MD, et al.
Foilsithe / Cruthaithe: (2017-10-01)

Saxagliptin Cardiotoxicity in Chronic Heart Failure: The Role of DPP4 in the Regulation of Neuropeptide Tone
de réir: Imre Vörös, et al.
Foilsithe / Cruthaithe: (2022-07-01)

Cholinergic control of heart rate by nitric oxide is site specific.
de réir: Herring, N, et al.
Foilsithe / Cruthaithe: (2002)

Neuropeptide-Y causes coronary microvascular constriction and is associated with reduced ejection fraction following ST-elevation myocardial infarction
de réir: Herring, N, et al.
Foilsithe / Cruthaithe: (2019)

The Role of Neuropeptide Y in Cardiovascular Health and Disease
de réir: Cheryl M. J. Tan, et al.
Foilsithe / Cruthaithe: (2018-09-01)

Pre-synaptic NO-cGMP pathway modulates vagal control of heart rate in isolated adult guinea pig atria.
de réir: Herring, N, et al.
Foilsithe / Cruthaithe: (2000)

Hyperhomocysteinemia and lipid peroxidation in stable coronary heart disease
de réir: O. L. Belaya, et al.
Foilsithe / Cruthaithe: (2007-02-01)

Effectiveness of different treatment regimens of enhanced external counterpulsation in patients with stable coronary artery disease complicated by heart failure
de réir: A. S. Lishuta, et al.
Foilsithe / Cruthaithe: (2024-03-01)

Secondary Prevention and Quality of Life of Patients with Stable Coronary Heart Disease
de réir: E. D. Zharkova, et al.
Foilsithe / Cruthaithe: (2023-05-01)

Perindopril effects on circadian heart rate variability in patients with coronary heart disease and stable angina
de réir: N. A. Shardanov, et al.
Foilsithe / Cruthaithe: (2007-08-01)

Left atrial measurements and adverse events in acute heart failure due to acute coronary syndrome
de réir: Yudelquis Ojeda-Riquenes, et al.
Foilsithe / Cruthaithe: (2020-05-01)

Immediate and Long-term Results of Stenting of the Unprotected Left Coronary Artery Trunk in Patients with Stable Coronary Heart Disease
de réir: G. K. Arutyunyan, et al.
Foilsithe / Cruthaithe: (2019-05-01)

The Risk of Adverse Drug-Drug Interactions for Stable Angina Pectoris Patients with Heart Failure Complication Prescribed Polypharmacy
de réir: Ahmad Aldi Fadillah, et al.
Foilsithe / Cruthaithe: (2023-09-01)

Mechanism of neuropeptide-Y-stimulated vasoconstriction in rat mesenteric and coronary arteries
de réir: Lin, J, et al.
Foilsithe / Cruthaithe: (2022)

Prediction of Thromboembolic Events in Heart Failure Patients in Sinus Rhythm: The Hong Kong Heart Failure Registry.
de réir: Jo-Jo Hai, et al.
Foilsithe / Cruthaithe: (2016-01-01)

Risk of stroke in patients with heart failure and sinus rhythm: data from the Swedish Heart Failure Registry
de réir: Clara Hjalmarsson, et al.
Foilsithe / Cruthaithe: (2021-02-01)

Coronary sinus, microanatomical study
de réir: Bexheti Ema, et al.
Foilsithe / Cruthaithe: (2022-01-01)

Psychological status and quality of life in patients with sick sinus syndrome and ischemic chronic heart failure
de réir: A. E. Кutuzova, et al.
Foilsithe / Cruthaithe: (2005-12-01)

Sinus arrhythmia effects on QT dispersion parameters in healthy individuals and coronary heart disease patients
de réir: P. Ya. Dovgalevsky, et al.
Foilsithe / Cruthaithe: (1970-01-01)

Mechanisms of respiratory sinus arrhythmia in patients with mild heart failure.
de réir: El-Omar, M, et al.
Foilsithe / Cruthaithe: (2001)

NO-cGMP pathway increases the hyperpolarisation-activated current, I(f), and heart rate during adrenergic stimulation.
de réir: Herring, N, et al.
Foilsithe / Cruthaithe: (2001)

NEUROPROTECTIVE PROPERTIES OF NEUROPEPTIDES
de réir: Kanunnikova N. P.
Foilsithe / Cruthaithe: (2017-12-01)

Clinical, haemodynamic, and pharmacological effects of withdrawal and reintroduction of digoxin in patients with heart failure in sinus rhythm after long term treatment.
de réir: Pugh, SE, et al.
Foilsithe / Cruthaithe: (1989)

Bisoprolol and sotalol for maintaining sinus rhythm in patients with paroxysmal atrial fibrillation and chronic heart failure
de réir: S. N. Tereshchenko, et al.
Foilsithe / Cruthaithe: (2005-12-01)